ADVM Stock Overview
A clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Adverum Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.90 |
| 52 Week High | US$29.70 |
| 52 Week Low | US$7.40 |
| Beta | 0.88 |
| 1 Month Change | -30.34% |
| 3 Month Change | -62.38% |
| 1 Year Change | -11.61% |
| 3 Year Change | -77.93% |
| 5 Year Change | -91.70% |
| Change since IPO | -96.86% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13
Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31Adverum ticks lower on underwhelming data from gene therapy in wet-AMD
Nov 16Shareholder Returns
| ADVM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.7% | 0.7% | 1.2% |
| 1Y | -11.6% | 5.0% | 27.7% |
Return vs Industry: ADVM underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: ADVM underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ADVM volatility | |
|---|---|
| ADVM Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ADVM's share price has been volatile over the past 3 months.
Volatility Over Time: ADVM's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 121 | Laurent Fischer | adverum.com |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. Fundamentals Summary
| ADVM fundamental statistics | |
|---|---|
| Market cap | US$163.15m |
| Earnings (TTM) | -US$112.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs ADVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADVM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$77.68m |
| Gross Profit | -US$77.68m |
| Other Expenses | US$35.22m |
| Earnings | -US$112.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ADVM perform over the long term?
See historical performance and comparison